BBI:NSD-Brickell Biotech Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.66

Change

+0.03 (+0.83)%

Market Cap

USD 9.98M

Volume

0.14M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

BBI Stock Forecast & Price:
Based on the Brickell Biotech Inc stock forecasts from 2 analysts, the average analyst target price for Brickell Biotech Inc is USD 0.00 over the next 12 months. Brickell Biotech Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Brickell Biotech Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Brickell Biotech Inc’s stock price was USD 3.66. Brickell Biotech Inc’s stock price has changed by -12.65% over the past week, -4.69% over the past month and -87.46% over the last year.

About Brickell Biotech Inc (BBI:NSD)

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which ha ...Read More

Company Website : https://www.brickellbio.com

Address : 5777 Central Avenue, Boulder, CO, United States, 80301

Employees : 16

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.08

52 Week High : 37.35

Short Ratio : 0.43

52 Week Low : 2.88

Shorted Shares : 176,185

200 Day Moving Average : 10.44

Shorted Shares Previous Month : 181,263

50 Day Moving Average : 4.84

Shares Held By Insiders : 1.31%

Short Percentage : 6.98%

Shares Held by Institutions : 15.95%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

-3.06 (-1.02%)

 USD75.25B 29.60 15.72
MRNA Moderna Inc

+3.13 (+1.83%)

 USD71.57B 5.79 4.08
REGN Regeneron Pharmaceuticals Inc

+19.34 (+3.11%)

 USD67.87B 12.49 9.34
BNTX BioNTech SE

+3.71 (+2.36%)

 USD40.37B 3.26 2.01
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
SGEN Seagen Inc

+0.05 (+0.03%)

 USD32.39B 55.02 -46.79
RPRX Royalty Pharma Plc

+0.25 (+0.57%)

 USD29.52B 42.40 20.35
ALNY Alnylam Pharmaceuticals Inc

+8.63 (+3.86%)

 USD27.16B N/A -34.32
GMAB Genmab AS

+0.56 (+1.59%)

 USD22.96B 73.23 6.37
ARGX argenx NV ADR

+0.21 (+0.06%)

 USD20.61B N/A -20.22

ETFs Containing BBI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -64.47% 18% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.47% 18% F 15% F
Trailing 12 Months  
Capital Gain -87.67% 8% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.67% 8% F 6% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -32.94% 9% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.94% 9% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 34.31% 81% B- 47% F
Risk Adjusted Return -96.00% 6% F 2% F
Market Capitalization 9.98M 3% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.69 83% B 89% B+
Price / Cash Flow Ratio -0.28 12% F 51% F
EV/EBITDA 0.15 29% F 54% F
Management Effectiveness  
Return on Equity -176.49% 16% F 7% F
Return on Invested Capital -153.37% 11% F 7% F
Return on Assets -85.20% 5% F 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.43 91% A- 87% B+
Short Percent 6.98% 32% F 25% F
Beta 0.08 93% A 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector